Pharma R&D Annual Review 2023

whitePaper | January 18, 2023

Reaching a post-pandemic era is an alluring prospect for almost everyone around the world after the disruptions of the past three years.

whitePaper | May 12, 2022

This document is Copyright © 2022 by the National Council for Prescription Drug Programs (NCPDP). It may be freely redistributed in its entirety provided this copyright notice is not removed.

whitePaper | December 20, 2022

Digitization of processes and data across the value chain along with the emergence of Internet of Things (IoT) has transformed the Pharma industry.

whitePaper | November 8, 2022

While drugs and devices differ in their development, clinical trial phases and regulatory guidelines, the most important difference is that medical devices do not achieve their principal action by pharmacological means.

whitePaper | September 16, 2022

T wice a year, we survey the cell and gene therapy landscape and ARM’s initiatives to advance the sector and provide an update to our members.

whitePaper | February 23, 2023

A period of substantial growth is an exciting time in the life of any company. For those in pharmaceutical contract research, development, or manufacturing.